Well, Scholar Rock holding on to gain since reporting that his spinal muscular atrophy drug helped patients on Eli Liy Zeppbound reduce muscle loss, a known risk factor tied to GLP1 obesity drugs. The drug is still in mid-stage trials for weight loss, but currently under FDA priority review to treat SMA, a genetic muscle wasting disease. Joining us now to dig into the results is Scholar Rock CEO David Halal.David, great to have you with us. Great to be with you, Melissa. Um, so walk us through the data beca ...